Navigation Links
Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
Date:8/17/2010

s a monotherapy and as an adjuvant agent as well," he added.

Xenon expects to conclude the phase 2 trial in Q1, 2011 with top-line data available in Q2, 2011.

About Xenon Pharmaceuticals Inc.

Xenon is a privately owned, clinical genetics-based drug discovery and development company engaged in developing small molecule therapies focusing in the areas of pain, cardiometabolic disease, and diseases of iron metabolism.  Xenon has multiple products in phase 1 and 2 clinical development.  For more information, visit the Company's website at www.xenon-pharma.com.

This release contains forward-looking statements that are not based on historical fact. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.


'/>"/>
SOURCE Xenon Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
2. CORRECTED: Ampio Pharmaceuticals Announces Completion of Negotiations for Acquisition of DMI BioSciences, Inc.
3. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
4. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
5. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
6. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
7. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
8. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
9. Angiotech Pharmaceuticals Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. (TSX-V: SQD; ... that develops and commercializes proprietary technologies and products ... it has received approval from the TSX Venture ... common share purchase warrants ("the Warrants") of the ... Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Global ... the GTCbio Stem Cell Summit 2015 April 27 - ... the latest developments in all areas of stem cell ... of stem cells and regenerative medicine. , The ... trials, as well as translational research in stem cell ...
(Date:4/16/2015)... Bythewood, South Carolina (PRWEB) April 17, 2015 ... solutions and steam system services, released their newly ... 2015. The customer facing website effectively promotes ... proposition. , All the information that a ... training, steam system services, company capabilities, industries serviced, ...
(Date:4/16/2015)... 2015 Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... results on Thursday, April 30, 2015 at 4:00 PM ... host a conference call at 4:30 PM Eastern Time ... outlook for the future. , The conference call will ... homepage and in the Investor Relations section of Cytokinetics’ ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... Inc.,(Nasdaq: ONTY ) (TSX: ONY) (the "Company") ... in a Phase 1b clinical trial of PX-12 ... proprietary small molecule,inhibitor of thioredoxin, a protein that ... survival and drug resistance of,many cancers., The ...
... and present a poster on proprietary siRNA ... targeting and ... Pharmaceuticals, Inc., a,development-stage pharmaceutical company discovering and developing novel,RNA ... Cambridge Healthcare Institute,s 9th Annual Beyond,Genome Conference on June ...
... Calif., June 10 DURECT Corporation,(Nasdaq: DRRX ... (NDA) for,Remoxy(TM) (ORADUR(TM)-based oxycodone) has been submitted to ... investigational drug, is a long,acting oral formulation of ... on DURECT,s ORADUR technology, Remoxy is designed to ...
Cached Biology Technology:Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 2Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 2New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 3New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 4New Drug Application Submitted for Remoxy(TM) (ORADUR(TM)-Based Oxycodone) 5
(Date:3/24/2015)... and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has announced ... 2015-2019" report to their offering. The ... at a CAGR of 23.5 percent over the period ... and the growth prospects of the Global Iris Recognition ... size, the report considers the revenue generated from sales ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... German . , Together with colleagues from ... for Allergy and Environment of the Technische Universitt Mnchen, ... major gene for allergic diseases. The gene was localized ... genome at the Helmholtz Zentrum Mnchen. The newly discovered ...
... of St. Andrews, United Kingdom, have helped determine why relearning ... cause a recollection of other associated, previously learned information. ... the learned information is forgotten. Details are published August ... When one learns a language and then doesn,t use ...
... 2008)-- U.S. Energy Secretary Samuel Bodman and Enrique Santacana, ... keynote speakers during GridWeek 2008 in Washington. ... and International Trade Center, is an annual gathering of ... major partner of GridWeek 2008. Bodman and ...
Cached Biology News:Munich researchers discover key allergy gene 2Energy secretary, IEEE-member industry leader to deliver keynote addresses during GridWeek 2008 2
Reported to support murine B lymphocytes, hematopoietic tissue from bone marrow, B cells stimulated with lipopolysaccharide, T lymphocytes, and a variety of hybrid cells....
... Many modifications of Eagle's ... the original formulation. The most ... Modified Eagle's,Medium. DME is a ... Eagle [MEM] that contains a ...
... Hollandes is a fixative useful for ... fixation. It is stable and will decalcify ... with Hollande's can be stained successfully with ... the solution stabilizes red blood cell membranes ...
... Gas Chromatograph/Mass Spectrometer, utilizing many of ... Plus, offers high throughput and excellent ... performance-to-cost ratio. Like the GCMS-QP2010 Plus, ... velocity for optimum separation, 20 temperature ...
Biology Products: